UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 25 ...
Filed by Alvotech (Commission...
Zusammenschluss soll voraussichtlich am bzw. um den 15. Juni 2022 abgeschlossen werden Stammaktien von Alvotech sollen ab 16. Juni 2022 am...
Le regroupement d'entreprises devrait être finalisé (vers) le 15 juin 2022 Les actions ordinaires d'Alvotech devraient être négociées sous le...
Business Combination anticipated to close on or about June 15, 2022 Ordinary shares of Alvotech expected to trade under the new ticker symbol...
Units, each consisting of one Class A ordinary share, $0.0001 par value, and one-fourth of one redeemable warrant false 0001820931 0001820931...
Business Combination remains subject to satisfaction of customary closing conditions, including shareholder approval Oaktree Acquisition Corp...
false 0001820931 0001820931 2022-05-31 2022-05-31 0001820931 oacb:UnitsEachConsistingOfOneClassAOrdinaryShare0.0001ParValueAndOneFourthOfOneRedee...
Filed by Alvotech (Commission File No. 333-261773) Pursuant to...
The confirmatory clinical, safety and efficacy study for AVT04, biosimilar candidate to Stelara® (ustekinumab) met its primary endpoint AVT04...
falseQ1Oaktree Acquisition Corp. II0001820931--12-31CAThe Company’s management has broad discretion with respect to the specific application...
Filed by Alvotech Lux Holdings S.A.S. (Commission File No. 333-261773) Pursuant to Rule 425 under the Securities Act...
- Results from pharmacokinetic (PK) similarity study demonstrate bioequivalence of AVT04 (ustekinumab) to the reference product...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.